![Nicholas Keher](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Nicholas Keher
Finanzdirektor/CFO bei
OXFORD NANOPORE TECHNOLOGIES PLC
Vermögen: 192 354 $ am 31.08.2026
Profil
Nicholas Patrick Keher is currently Director at Idis Ltd. since 2019 and Director at Idis Group Holdings Ltd. since 2019.
Former roles include Chief Financial Officer at BenevolentAI SA from 2022 to 2023; Group Chief Financial Officer & Director at Clinigen Ltd. from 2019 to 2021; Director at Iovance Biotherapeutics UK SP Ltd. from 2019 to 2021; Director at Clinigen Holdings Ltd.; Managing Director at Royal Bank of Canada from 2015 to 2019; Analyst at RBC Europe Ltd. (Broker) from 2015 to 2016; and Research Analyst at Investec Bank Plc (Broker) from 2011 to 2015.
Education includes graduation from the University of Aston.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 12.08.2026 | 80’467 ( 0.01% ) | 192 354 $ | 31.08.2026 |
Aktive Positionen von Nicholas Keher
| Unternehmen | Position | Beginn |
|---|---|---|
| OXFORD NANOPORE TECHNOLOGIES PLC | Finanzdirektor/CFO | 22.01.2024 |
Idis Group Holdings Ltd.
 Idis Group Holdings Ltd. MiscellaneousMiscellaneous Operates as a holding company | Direktor/Vorstandsmitglied | 19.03.2019 |
Idis Ltd.
 Idis Ltd. Drugstore ChainsRetail Trade Supplies pharmaceuticals and allied services to the healthcare industry | Direktor/Vorstandsmitglied | 19.03.2019 |
Ehemalige bekannte Positionen von Nicholas Keher
| Unternehmen | Position | Ende |
|---|---|---|
| BENEVOLENTAI S.A. | Finanzdirektor/CFO | 25.05.2023 |
| CLINIGEN GROUP PLC | Finanzdirektor/CFO | 25.08.2021 |
Clinigen SP Ltd.
 Clinigen SP Ltd. Pharmaceuticals: MajorHealth Technology Manufactures and sells pharmaceutical products | Direktor/Vorstandsmitglied | 24.08.2021 |
| ROYAL BANK OF CANADA | Corporate Officer/Principal | 01.03.2019 |
RBC Europe Ltd. (Broker)
 RBC Europe Ltd. (Broker) Investment Banks/BrokersFinance Provides brokerage services | Analyst-Equity | 06.03.2016 |
Ausbildung von Nicholas Keher
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
71
Beziehungen ersten Grades
11
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 11 |
|---|---|
Royal Bank of Canada
 Royal Bank of Canada Major BanksFinance Operates as a national commercial bank | Finance |
Oxford Nanopore Technologies Plc
 Oxford Nanopore Technologies Plc Electronic Equipment/InstrumentsElectronic Technology Develops instruments for electronic detection and analysis of molecules | Electronic Technology |
Idis Ltd.
Idis Ltd. Drugstore ChainsRetail Trade Supplies pharmaceuticals and allied services to the healthcare industry | Retail Trade |
University of Aston
 University of Aston Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
RBC Europe Ltd. (Broker)
RBC Europe Ltd. (Broker) Investment Banks/BrokersFinance Provides brokerage services | Finance |
Idis Group Holdings Ltd.
Idis Group Holdings Ltd. MiscellaneousMiscellaneous Operates as a holding company | Miscellaneous |
Investec Bank Plc (Broker)
 Investec Bank Plc (Broker) Investment Banks/BrokersFinance Provides brokerage services | Finance |
Clinigen Ltd.
 Clinigen Ltd. Miscellaneous Commercial ServicesCommercial Services Operates as a pharmaceutical services company that engages in clinical trails, regulatory affairs, distribution and commercialization of pharma companies | Commercial Services |
Clinigen SP Ltd.
Clinigen SP Ltd. Pharmaceuticals: MajorHealth Technology Manufactures and sells pharmaceutical products | Health Technology |
Clinigen Holdings Ltd.
 Clinigen Holdings Ltd. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
BenevolentAI SA
 BenevolentAI SA Packaged SoftwareTechnology Services Develops AI drug discovery platform to accelerate biopharma drug discovery | Technology Services |
